Focused On-demand Library for PH-interacting protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8WWQ0

UPID:

PHIP_HUMAN

Alternative names:

DDB1- and CUL4-associated factor 14; IRS-1 PH domain-binding protein; WD repeat-containing protein 11

Alternative UPACC:

Q8WWQ0; A7J992; B2RPK4; Q05CQ9; Q5VVH4; Q66I29; Q69YV1; Q8NBZ5; Q96H52; Q96ME2; Q9H261

Background:

PH-interacting protein, also known as DDB1- and CUL4-associated factor 14, IRS-1 PH domain-binding protein, and WD repeat-containing protein 11, plays a crucial role in cellular processes. It is a probable regulator of insulin and insulin-like growth factor signaling pathways, stimulating cell proliferation via cyclin transcription regulation and possessing anti-apoptotic activity through AKT1 phosphorylation.

Therapeutic significance:

Linked to Chung-Jansen syndrome, characterized by developmental delay and intellectual disability, PH-interacting protein's understanding could pave the way for innovative therapeutic strategies targeting this autosomal dominant disorder.